Eliza Marroni
Psychiatric/Mental Health · Grand Junction, CONPI 1083181192
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $11,900 of the $17,476 with a category attached, or 68.1%. AbbVie accounts for 86.2% of it on its own, with 14 other manufacturers making up the rest. Reporting peaked in 2023 at $6,610 and has fallen 95.2% since, to $318 in 2025. Among psychiatric/mental health clinicians in CO with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 184 payments — averaging $94.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$15K
- Neurocrine Biosciences, Inc.$655
- Lundbeck LLC$429
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$382
- Alkermes, Inc.$245
- Sunovion Pharmaceuticals Inc.$171
- plus $523 from 9 others
What the payments were for
- Speaking & faculty fees$11,90068%
- Travel & lodging$1,99011%
- Food & beverage$3,53920%
- Education$470%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 89 | $15,072 |
| Neurocrine Biosciences, Inc. | 11 | $655 |
| Lundbeck LLC | 35 | $429 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 5 | $382 |
| Alkermes, Inc. | 10 | $245 |
| Sunovion Pharmaceuticals Inc. | 13 | $171 |
| Otsuka America Pharmaceutical, Inc. | 8 | $150 |
| Vanda Pharmaceuticals Inc. | 2 | $147 |
| Teva Pharmaceuticals USA, Inc. | 3 | $63 |
| Johnson & Johnson | 2 | $53 |
| Eisai Inc. | 2 | $29 |
| Axsome Therapeutics, Inc. | 1 | $28 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $23 |
| Bioxcel Therapeutics, Inc. | 1 | $18 |
| Corium, LLC | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$17,476 in reported general payments places this provider in the 95th percentile of 873 psychiatric/mental health providers in Colorado.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 46 | $385,178 |
| Invega SustennaPaliperidone Palmitate | 112 | $316,465 |
| VraylarCariprazine Hcl | 100 | $146,171 |
| AustedoDeutetrabenazine | 26 | $140,533 |
| RexultiBrexpiprazole | 84 | $138,822 |
| UzedyRisperidone | 22 | $113,585 |
| FanaptIloperidone | 22 | $48,098 |
| TrintellixVortioxetine Hydrobromide | 46 | $22,495 |
| AuvelityDextromethorphan Hbr/Bupropion | 18 | $17,760 |
| BelsomraSuvorexant | 36 | $17,680 |
| ZyprexaOlanzapine | 11 | $16,522 |
| Clozapine | 157 | $12,285 |
| Methylphenidate ErMethylphenidate Hcl | 23 | $8,519 |
| Lurasidone Hcl | 105 | $8,295 |
| Paliperidone ErPaliperidone | 38 | $6,252 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Neurocrine Biosciences, Inc.Ingrezza | $655 | $385,17846 claims |
| Johnson & JohnsonInvega Sustenna | $53 | $316,465112 claims |
| Teva Pharmaceuticals USA, Inc.Austedo, Uzedy | $63 | $254,11848 claims |
| AbbVieVraylar | $15,072 | $146,171100 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $150 | $138,82284 claims |
| Vanda Pharmaceuticals Inc.Fanapt | $147 | $48,09822 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $23 | $22,49546 claims |
| Axsome Therapeutics, Inc.Auvelity | $28 | $17,76018 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 873 psychiatric/mental health providers in Colorado.
Other psychiatric/mental health in Grand Junction
- Heather ScottGrand Junction$17K
- Chelsie MonroeLittleton$998K
- Audrey StrockDenver$499K
- Pinkie FittsAurora$444K
- Mark JankelowColorado Springs$287K
- Cristi BundukamaraColorado Springs$230K
- Deborah YorkDenver$158K
- Shelley AbadiLakewood$19K
- James AndersonWheat Ridge$18K
- Sylvia KingPueblo West$17K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.